Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Body Surface Potential Mapping | 1 | 2017 | 20 | 0.72 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2017 | 193 | 0.58 | Why? |
| Heart-Assist Devices | 3 | 2017 | 812 | 0.55 | Why? |
| Cardiomyopathy, Dilated | 1 | 2017 | 251 | 0.55 | Why? |
| Heart Conduction System | 1 | 2017 | 266 | 0.54 | Why? |
| Tachycardia, Ventricular | 1 | 2017 | 251 | 0.54 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.53 | Why? |
| Catheter Ablation | 1 | 2017 | 438 | 0.49 | Why? |
| Atrial Fibrillation | 3 | 2021 | 2320 | 0.46 | Why? |
| Transportation of Patients | 1 | 2017 | 494 | 0.45 | Why? |
| Registries | 10 | 2021 | 12327 | 0.44 | Why? |
| Shock, Cardiogenic | 2 | 2017 | 700 | 0.43 | Why? |
| Patient Transfer | 1 | 2017 | 898 | 0.40 | Why? |
| Heart Failure | 6 | 2021 | 6638 | 0.22 | Why? |
| Hypernatremia | 1 | 2020 | 182 | 0.19 | Why? |
| Heart Diseases | 3 | 2021 | 3503 | 0.19 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2017 | 5002 | 0.19 | Why? |
| Polycythemia | 1 | 2018 | 19 | 0.18 | Why? |
| Maltose | 1 | 2018 | 50 | 0.18 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.18 | Why? |
| Heart Defects, Congenital | 2 | 2018 | 933 | 0.18 | Why? |
| Ventricular Function, Left | 2 | 2017 | 1555 | 0.17 | Why? |
| Cholesterol, LDL | 1 | 2021 | 499 | 0.17 | Why? |
| Stroke | 1 | 2021 | 8839 | 0.17 | Why? |
| Ferric Compounds | 1 | 2018 | 136 | 0.17 | Why? |
| Ventricular Fibrillation | 1 | 2018 | 126 | 0.16 | Why? |
| Coma | 1 | 2018 | 204 | 0.16 | Why? |
| Hypothermia, Induced | 1 | 2018 | 176 | 0.16 | Why? |
| Hyponatremia | 1 | 2020 | 371 | 0.16 | Why? |
| Heart Valve Prosthesis | 2 | 2020 | 533 | 0.14 | Why? |
| Cardiovascular Agents | 1 | 2021 | 663 | 0.14 | Why? |
| Dyslipidemias | 1 | 2021 | 791 | 0.14 | Why? |
| Mitral Valve | 1 | 2017 | 342 | 0.13 | Why? |
| Critical Care | 1 | 2017 | 14081 | 0.13 | Why? |
| Death, Sudden, Cardiac | 1 | 2018 | 522 | 0.12 | Why? |
| Iron | 1 | 2018 | 619 | 0.12 | Why? |
| Endocarditis | 1 | 2017 | 368 | 0.12 | Why? |
| Coronary Disease | 1 | 2018 | 645 | 0.11 | Why? |
| Respiratory Insufficiency | 3 | 2021 | 7301 | 0.11 | Why? |
| Out-of-Hospital Cardiac Arrest | 2 | 2018 | 1047 | 0.11 | Why? |
| Myocardial Infarction | 2 | 2018 | 3361 | 0.11 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.11 | Why? |
| Noninvasive Ventilation | 2 | 2021 | 2329 | 0.11 | Why? |
| Risk Assessment | 5 | 2021 | 25439 | 0.11 | Why? |
| Acute Kidney Injury | 2 | 2021 | 5762 | 0.10 | Why? |
| Prognosis | 10 | 2021 | 32490 | 0.10 | Why? |
| Taste Disorders | 1 | 2021 | 1720 | 0.10 | Why? |
| Aged | 19 | 2021 | 215776 | 0.10 | Why? |
| Hypertension, Pulmonary | 1 | 2018 | 970 | 0.09 | Why? |
| Thrombolytic Therapy | 2 | 2017 | 2218 | 0.09 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.09 | Why? |
| Heart Ventricles | 1 | 2017 | 1139 | 0.09 | Why? |
| Image Processing, Computer-Assisted | 1 | 2017 | 1383 | 0.09 | Why? |
| Acute Coronary Syndrome | 1 | 2021 | 2107 | 0.09 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Male | 21 | 2021 | 367725 | 0.08 | Why? |
| Sepsis | 2 | 2021 | 3517 | 0.08 | Why? |
| Heart Arrest | 1 | 2018 | 1239 | 0.08 | Why? |
| Risk Factors | 9 | 2021 | 71621 | 0.08 | Why? |
| Endovascular Procedures | 1 | 2016 | 1302 | 0.08 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 5277 | 0.08 | Why? |
| Female | 21 | 2021 | 380317 | 0.08 | Why? |
| Multivariate Analysis | 3 | 2021 | 5440 | 0.07 | Why? |
| Fibrinolytic Agents | 1 | 2017 | 1702 | 0.07 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.07 | Why? |
| Survival Rate | 4 | 2020 | 9206 | 0.07 | Why? |
| Spain | 5 | 2021 | 15545 | 0.07 | Why? |
| Humans | 28 | 2021 | 930598 | 0.07 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.07 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.07 | Why? |
| Proportional Hazards Models | 3 | 2021 | 6543 | 0.06 | Why? |
| Arrhythmias, Cardiac | 1 | 2017 | 2510 | 0.06 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Propensity Score | 2 | 2020 | 2690 | 0.06 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.06 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.05 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.05 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.05 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Treatment Outcome | 4 | 2018 | 51732 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Hematinics | 1 | 2018 | 48 | 0.05 | Why? |
| Erythropoiesis | 1 | 2018 | 71 | 0.04 | Why? |
| Exercise | 1 | 2018 | 6771 | 0.04 | Why? |
| Dobutamine | 1 | 2016 | 36 | 0.04 | Why? |
| Pulmonary Embolism | 1 | 2016 | 4775 | 0.04 | Why? |
| Hospitals | 1 | 2017 | 11793 | 0.04 | Why? |
| Norepinephrine | 1 | 2016 | 152 | 0.04 | Why? |
| Echocardiography, Three-Dimensional | 1 | 2017 | 135 | 0.04 | Why? |
| Contraindications, Drug | 1 | 2016 | 281 | 0.04 | Why? |
| Respiration, Artificial | 4 | 2021 | 22116 | 0.04 | Why? |
| Factor Xa Inhibitors | 1 | 2020 | 490 | 0.04 | Why? |
| Prosthesis Failure | 1 | 2017 | 195 | 0.04 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.04 | Why? |
| Creatinine | 1 | 2021 | 1443 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Abscess | 1 | 2017 | 234 | 0.04 | Why? |
| Syncope | 1 | 2018 | 238 | 0.04 | Why? |
| Thrombosis | 1 | 2017 | 7504 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.03 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2020 | 552 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Hematologic Tests | 1 | 2018 | 521 | 0.03 | Why? |
| Renal Insufficiency | 1 | 2020 | 810 | 0.03 | Why? |
| L-Lactate Dehydrogenase | 1 | 2021 | 1995 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Italy | 3 | 2021 | 38444 | 0.03 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.03 | Why? |
| Sports | 1 | 2018 | 690 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2021 | 2654 | 0.02 | Why? |
| Adult | 5 | 2018 | 244371 | 0.02 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Heparin | 1 | 2020 | 2600 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2016 | 3395 | 0.02 | Why? |
| United Kingdom | 2 | 2018 | 18046 | 0.02 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Germany | 1 | 2021 | 9196 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.02 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.02 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |